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Abstract
Background: Preventable adverse drug events (pADEs) are widely known to be a health care issue for hospitalized
patients. Surgical patients are especially at risk, but prevention of pADEs in this population is not demonstrated
before. Ward-based pharmacy interventions seem effective in reducing pADEs in medical patients. The cost-
effectiveness of these preventive efforts still needs to be assessed in a comparative study of high methodological
standard and also in the surgical population. For these aims the SUREPILL (Surgery & Pharmacy in Liaison) study is
initiated.
Methods/Design: A multi-centre controlled trial, with randomisation at ward-level and preceding baseline
assessments is designed. Patients admitted to the surgical study wards for elective surgery with an expected
length of stay of more than 48 hours will be included. Patients admitted to the intervention ward, will receive
ward-based pharmacy care from the clinical pharmacy team, i.e. pharmacy practitioners and hospital pharmacists.
This ward-based pharmacy intervention includes medication reconciliation in consultation with the patient at
admission, daily medication review with face-to-face contact with the ward doctor, and patient counselling at
discharge. Patients admitted in the control ward, will receive standard pharmaceutical care.
The primary clinical outcome measure is the number of pADEs per 100 elective admissions. These pADEs will be
measured by systematic patient record evaluation using a trigger tool. Patient records positive for a trigger will be
evaluated on causality, severity and preventability by an independent expert panel. In addition, an economic
evaluation will be performed from a societal perspective with the costs per preventable ADE as the primary
economic outcome. Other outcomes of this study are: severity of pADEs, number of patients with pADEs per total
number of admissions, direct (non-)medical costs and indirect non-medical costs, extra costs per prevented ADE,
number and type of pharmacy interventions, length of hospital stay, complications registered in a national
complication registration system for surgery, number of readmissions within three months after initial admission
(follow-up), quality of life and number of non-institutionalized days during follow-up.
Discussion: This study will assess the cost-effectiveness of ward-based pharmacy care on preventable adverse drug
events in surgical patients from a societal perspective, using a comparative study design.
Trial registration: Netherlands Trial Register (NTR): NTR2258
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Incidents caused by medications are a widely recognized
issue in hospitalised patients. These incidents are known
as Adverse Drug Events (ADEs), usually defined as ‘any
injury due to the use of medication’ [1]. These may
occur as an unavoidable result of the pharmacological
action (side effect or Adverse Drug Reaction) or by the
manner in which a drug is applied (medication error or
substandard care). A preventable ADE (pADE) is
defined as ‘a n yi n j u r yc a u s e db yam e d i c a t i o ne r r o r ’.
These pADEs are associated with substantial mortality
and morbidity rates [2]. Besides clinical consequences,
preventable ADEs have a considerable impact on health
care costs [3,4].
A recent systematic review shows that 15.1% of all in-
hospital adverse events (AEs), is medication related (i.e.
ADEs) [5]. Current estimates show a large variance in
the incidence of preventable ADEs–i.e. from 0.6 - 16
per 100 admissions [4,6-14], due to variability in popula-
tion and variability in the sensitivity of detection meth-
ods. Surgical patients are typically at risk due to the
transfer moments of surgical patients, medication
changes before and after surgical intervention and a
relatively frequent use of medications associated with a
high prevalence of AEs, such as analgesics, anticoagu-
lants and antibiotics [5,9]. The incidence of pADEs in
surgical patients is unclear because of the absence of
large studies using a standardized and general applicable
detection method to determine pADEs in the surgical
population.
In order to reduce the incidence and costs of in-hos-
pital ADEs, several computerized strategies are devel-
oped, e.g. computerized order checking, barcode
medication administration or computerized physician
order entry (CPOE) with clinical decision-support sys-
tem [10]. However, even in highly computerized hospi-
tals, high rates of preventable ADEs remain [12].
Among health care professionals within the hospital
organization, clinical pharmacists can fulfil a vital role
in improving medication safety by face-to-face interac-
tion with physicians and patients [15-17]. Instead of
fulfilling the responsibility for the appropriate, safe and
cost-effective use of medication from a central phar-
macy, without patient contact or direct access to infor-
mation on the clinical status of the patient and
without face-to-face contact with the physician or
nurses, nowadays active participation of pharmacists in
the ward is common practice in countries such as the
UK, USA and Australia [15]. This active participation
of hospital pharmacists in the clinical process–also
known as ‘ward-based pharmacy care’–can reduce the
occurrence of ADEs effectively with 66%-78% in medi-
cal and intensive care units [16,17]. Their activities
consist of close review of medication at admission,
active participation in multidisciplinary rounding
teams, and counselling patients at discharge [15].
Only few studies have investigated the economic
impact of the contribution of pharmacists to the clini-
cal process [18-20]. Bond et al. studied the associations
between clinical pharmacy services and total cost of
care in approximately 1000 general surgery hospitals in
the US. Clinical pharmacy services were associated
with a cost saving per hospital per year of 5-8 million
USD [18].
The departments of hospital pharmacy and surgery
in the Academic Medical Centre in Amsterdam, The
Netherlands, initiated the SUREPILL study: Surgery &
Pharmacy in Liaison. The goal of this comparative study
is to evaluate whether ward-based clinical pharmacy
care can reduce (preventable) adverse drug events cost-
effectively in elective surgical patients. The economic
impact will be assessed from a societal perspective with
incremental cost-effectiveness analyses of clinical phar-
macy interventions against standard care. According to
a recent systematic review there still is a need for
comparative studies of high methodological standard
measuring the effect of clinical pharmacy interventions
in general [21]. Moreover, incidence of pADEs and pre-
ventability by a ward-based pharmacy team in surgical
patients with more complex use of medication is not yet
evaluated.
The main purpose of the SUREPILL study is to answer
the following questions: 1) Will active participation of a
clinical pharmacy team in surgical wards reduce preven-
table ADEs? 2) Will a clinical pharmacy team be cost-
effective in reducing preventable ADEs in surgical wards
receiving ward-based pharmacy compared to control
wards receiving standard pharmaceutical care?
Methods/Design
Design
To answer the research questions, a multi-centre con-
trolled trial, with randomisation at ward-level is
designed. Participating centres are the Academic Medi-
cal Centre (AMC), the Onze Lieve Vrouwe Gasthuis
(OLVG) in Amsterdam and the Diakonessenhuis in
Utrecht. In each centre at least two surgical wards will
participate. These study wards contain mainly gastro-
intestinal and vascular surgical patients.
The study design is depicted schematically in figure 1.
First, baseline assessments in each hospital in the parti-
cipating surgical wards will be performed. Then, in each
centre, one ward will be randomly assigned (one-time
randomisation) as intervention ward, receiving ward-
based pharmacy care, whereas the other ward(s) will
serve as control ward, receiving standard pharmaceutical
care from the central hospital pharmacy (i.e. current
daily practice).
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Consecutive patients admitted to the surgical study
wards for elective surgery with an expected length of
stay of more than 48 hours will be included. Patients
transferred from another hospital or from another ward
within the hospital are excluded. Cross-over between
the study wards will exclude the patient. Patients already
included in the study will not be included for a second
time in a following admission.
After evaluation by the Medical Ethics Committee
(MEC) at the coordinating center (AMC Amsterdam) it
has been decided that this study is exempt from ethical
approval, because this study does not meet the criteria
for Medical Scientific Research with humans under the
Figure 1 SUREPILL study design and assessment.
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was therefore not required. Furthermore, this protocol
has been peer reviewed before study approval by the
Dutch National Grant Committee of Health Care Effi-
ciency Research (ZonMw grant 170882706).
Intervention
Standard care
In all wards during baseline assessment and in control
wards during the intervention phase, patients will
receive standard pharmaceutical care from a pharmacy
team in the traditional role of taking the responsibility
for the appropriate, safe and cost-effective use of medi-
cation from a central pharmacy. This does not include
patient contact or direct access to patients’ medical
records, nor does it include face-to-face contact with
the ward doctors or nurses. The activities regarding
individual patient pharmaceutical care consists of provi-
sion of community pharmacy data to the ward at
admission, daily screening of alerts generated by the
CPOE-system by the pharmacists during hospitalisation
and provision of a discharge medication list for the
community pharmacy.
Ward-based pharmacy care
A clinical pharmacy team will perform the ward-based
pharmacy interventions. This team consists of pharmacy
practitioners (pharmacy technicians, who completed
additional training for ward-based pharmacy interven-
tions) and hospital pharmacists.
Patients admitted at an intervention ward will receive
bedside care from the ward-based pharmacy team.
These interventions are tailored to cover critical steps in
the medication process during the surgical pathway. On
admission the pharmacy practitioner will perform medi-
cation reconciliation in consultation with the patient.
This includes verification of the current use of commu-
nity pharmacy medication. During hospitalisation the
hospital pharmacist will review the medication charts
daily and will optimise drug therapy when needed. The
pharmacist combines information from CPOE-alerts,
laboratory results and medical record information, in
liaison with the ward doctor (face-to-face communica-
tion). At discharge the pharmacy practitioner will review
the medication prescriptions by comparing them with
the medication at admission. Unintended discrepancies
will be discussed with the ward doctor. In addition, the
pharmacy practitioner will perform patient counselling
and send a complete list of discharge medication to the
community pharmacy and general practitioner.
Study outcomes and data collection
The primary outcome parameter is the number of pre-
ventable ADEs per 100 admissions. Secondary outcome
parameters are severity of preventable ADEs, number of
patients with preventable ADEs per total number of
admissions, direct (non-)medical costs and indirect non-
medical costs, extra costs per prevented ADE, number
and type of pharmacy interventions, length of hospital
stay, complications registered in a national complication
registration system for surgery, number of readmissions
within three months after the initial admission (follow-
up), quality of life during follow-up and number of non-
institutionalized days during follow-up.
To assess the incidence and severity of preventable
ADEs, we will systematically evaluate patient records
and the hospital information system by use of a devel-
oped and validated Trigger Tool. This tool is based on
previously literature on trigger tools, such as the trigger
tool for measuring harm in ICU patients [22], the trig-
ger tool for detection of AEs in surgical patients [23]
and the widely used Global Trigger Tool of the Institute
for Healthcare Improvement [24,25]. This list of items,
or triggers, are clues to identify potential pADEs. Pre-
vious studies have shown that a trigger tool can effi-
ciently and consistently be applied to detect and identify
preventable ADEs [26,27]. If patient records are positive
for potential pADE triggers, an independent expert
panel, consisting of senior hospital pharmacists and con-
sultant surgeons, will assess the presence or absence of
the potential pADE individually, blinded for the hospital
and ward the patient was admitted to. They will deter-
mine the presence or absence by use of a causality
assessment tool for surgical patients based on tools such
a st h eN a r a n j op r o b a b i l i t ys c o r ea n dt h eW H O - U M C
[28,29].
Besides causality assessment, the expert panel will also
determine the severity of the ADE by use of a classifica-
tion system called Common Terminology Criteria for
Adverse Events (CTCAE) developed by the U.S.
National Cancer institute [30]. This list is preferred,
because a grading scale is provided for each AE term, in
contrast to the National Coordinating Council for Medi-
cation Error Reporting and Prevention index (NCC
MERP) [31]. Furthermore, the expert panel will assess
the additional impact of each pADE to a patient’sl i f e ,
given his disease status. Discrepancies between the indi-
vidual assessments will be discussed at consensus meet-
ings of the experts.
For the economic evaluation, we will collect direct
medical costs of all included admissions, such as diag-
nostic examinations, therapeutic interventions as well as
the costs of monitoring by hospital pharmacists during
hospitalization. Most data will be extracted from the
hospital information system. Specifically, registration of
tasks performed by the clinical pharmacy team will be
done, not just as input values for the cost estimates, but
also to support implementation decisions in anticipation
of the program’s cost-effectiveness. Moreover, we will
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as costs of out-patients care, out-of-hospital care and, if
opportune, readmissions, as well as on indirect non-
medical costs, such as productivity losses, by sending a
patient questionnaire at three months following hospital
admission. This questionnaire consists of an adapted
version of the Health and Labour questionnaire devel-
oped by the Institute for Medical Technology Assess-
ment in the Netherlands [32].
Besides cost-related questions, the validated EQ-5D
questionnaire is used at three months after the initial
admission to measure the quality of life of the patient
[33]. The EQ-5D instrument contains five dimensions
(mobility, self care, usual activities, pain/discomfort and
anxiety/depression) for which patients have to indicate
whether they experienced no, some or severe/extreme
problems. In addition, patients have to assess their
health status on a Visual Analogue Scale (VAS), ranging
from zero for the worst imaginable health state to 100
for the best imaginable health state [33].
During the intervention period, we will document all
interventions in the intervention wards performed by
the clinical pharmacy team. In this study an intervention
is defined as every change made in the patient’sf a r m a -
cotherapeutic management due to advice of one of the
pharmacy team members. These interventions will be
documented using a classification that is based on pre-
vious described types of interventions in literature [34].
The categories of this classification are listed in table 1.
Sample size and data analysis
The power calculation is based on the parallel compari-
son of the number of pADEs per 100 admissions
between patients admitted at the intervention ward
(with ward-based pharmacy care) and those admitted at
the control ward (with standard care). We expect a
mean base rate of five preventable ADEs per 100
admissions in the control group. This rate is conserva-
tively estimated, based on the incidence of pADEs per
100 admissions in prospective observational studies in
hospitalised patients (pooled mean 2.1%, range: 0.6%-
16.2% [4,6-14]) and observed rates in control groups of
intervention studies on the effect of clinical pharmacy
on pADEs (pooled mean 11.6%, range: 11.4%-12%
[16,17,26,35]). The difference in incidence rate between
the observational and intervention studies can be predo-
minantly explained by a higher sensitivity of ADE detec-
tion methods employed in the intervention studies.
In this study population, we hypothesize a relative
reduction in pADEs of 60%. This hypothesis is based on
the findings of two controlled studies assessing ward-
based pharmacy in non-surgical wards, showing a reduc-
tion of 66% and a reduction of 78% [16,17].
With all admissions equally distributed over interven-
tion and control wards, a sample of 964 admissions
achieves 80% power at a 0.05 one-sided significance
level to detect a reduction in the number of pADEs per
100 admissions from 5 to 2 or below (rate ratio <0.4),
resulting from ward-based pharmacy care compared to
standard care. To control for ward-specific ADEs at
baseline, 480 patients equally distributed over the parti-
cipating surgical wards, will be included at start. Hence,
the total number of patients amounts to 1444 (480 +
964). This number of patients will be distributed over
the participating centres according to their proportion
of number of admitted patients in the wards.
With the total number of 1444 patients a Poisson
regression of the number of pADEs with the type of
treatment (intervention or control) as the main covariate
of interest can be performed to detect a rate ratio below
0.4 with 80% power at a significance level of 0.05. This
is performed while adjusting for other covariates like,
for instance, hospital site, ward type, observation period,
ADE levels at baseline, and patient age, even if these
other covariates explain as much as 50% of the variance
in pADE counts by type of treatment.
Because the number of pADEs per 100 admissions in
the control condition is probably conservatively esti-
mated, a recalculation of the needed sample size will be
performed when the baseline pADE counts become
available.
Economic evaluation
The economic evaluation of ward-based pharmacy care
compared with standard care will be performed as a cost-
effectiveness analysis from a societal perspective with the
costs per preventable ADE as the primary outcome mea-
sure. Although fewer ADEs may result in reduced utiliza-
tion of hospital resources, the savings may well be offset
by increased pharmacy staff time. The time horizon of
the evaluation will be three months following the initial
admission to the surgery ward. This follow-up period will
Table 1 Types of interventions
Intervention Including
Provision of drug information physicians and nurses
Change route of administration e.g., intravenous to oral
Drug dosage adjustment sub- or supratherapeutic
Drug frequency adjustment sub- or supratherapeutic
Recommendendation of
monitoring
drug interaction, toxicology, allergy,
adverse drug events
Suggest initiation of drug
therapy
untreated indication
Recommendation of
alternative drug therapy
formulary changes, drug interaction
Suggest discontinuing drug
therapy
toxicology, allergy, adverse drug event,
drug duplication
Others not listed above
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as some time post-discharge. With this short time-span,
costs and effects will not be discounted. Incremental
cost-effectiveness ratios will be calculated, reflecting the
difference in costs between ward-based pharmacy care
and standard care relative to the difference in number of
preventable ADEs.
Sensitivity analyses will be performed to account for
sampling variability, plausible ranges of ward costs of
various health care components, the substitution of
pharmacists by pharmacy technicians and the weighing
of preventable ADEs by level of severity based on expert
opinion and using the CTCAE classification system.
Furthermore, scenario analyses will be performed to
account for differential allocations of ward-based phar-
macy care during admissions. By monitoring the occur-
rence of preventable ADEs during admissions, ADE risk
profiles over time (e.g. probabilities of events at day 1,
day 2, etc.) can be constructed and used to develop sce-
narios for discontinuous or intermittent ward-based
pharmacy care during admissions. Such scenarios may
save costs which can be weighed against the risk of
missing preventable ADEs.
Unit costs resources used will be derived from the
most actual Dutch costing guideline for health care
research [36]. The friction costs method will be applied
to derive the costs of productivity loss due to sick leave
from work [37]. After price-indexing all costs will be
expressed in Euros for the base year 2010.
Discussion
Measuring cost-effectiveness of clinical pharmacy is
complex. Criteria for such research are not standardized.
Recently, several recommendations have been stated in a
systematic review [21], such as comparative design
including a control group, providing details of clinical
pharmacy interventions, considering health benefits,
considering the effect of program factors (e.g. type of
ward and hospital, and level of expertise of clinical phar-
macist), considering applicability in other settings, taking
a societal perspective when evaluating clinical pharmacy
interventions, and including sensitivity and incremental
cost-effectiveness analyses. The present study design
meets these criteria.
For this study we choose a parallel design with pre-
ceding baseline assessment and with randomisation at
ward level to assess the incidence of pADEs at baseline
in the participating study wards and to determine the
impact of the ward-based pharmacy care as well as to
take into account the impact of differences between the
observed study wards. Furthermore, a large number of
factors are suggested to increase the risk of ADEs in
hospitalised patients, such as drug characteristics (e.g.
route of administration), patient-specific factors (e.g.
number of medications taken) [9] and organisational
factors (e.g. communication) [38]. These drug character-
istics, patient-specific and organisational factors influ-
ence the incidence and severity of ADEs, but it is
unknown to what extent. Therefore, the ideal situation
to test the impact of a pharmacy team on clinical and
economic outcomes would consist of an equal distribu-
tion of all these factors in experimental and control
group. Straightforward comparison of two wards, with
one ward only experimental and the other ward only
control patients, implies the risk of unbalanced confoun-
ders because of the differences between the wards,
patients and its staffing. By adding a baseline assessment
it is possible to adjust for a priori differences between
wards. In this manner a clear insight of the sole impact
of the ward-based pharmacy care on pADEs is obtained.
We choose not to randomise at patient level within a
ward because this would imply that one medical team
provides care to both experimental and control patients
concurrently. The drawback of this design is that the
medical staff confronted with the pharmacy team has an
increased awareness level of medication safety while
they are treating control patients at the same time. This
effect is know as the ‘Hawthorne effect’–affecting the
standard care in control patients [39]. In other words,
experimental and control patients in one ward together
implies a substantial risk of contamination of arms and
thus blurring of effects on outcomes. Therefore, we
choose a randomised design on ward level. Thus, in
each participating centre, one ward is assigned as
experimental (intervention) ward, whereas the other(s)
will serve as control ward.
To reduce the risk of confounding, a spaced rando-
mised design including ‘cross over’ would be desirable.
Hereby each ward will serve as control and experimental
ward separated with a wash-out period. However, this
design was considered of limited value, because wash-
out of learning experiences in the intervention arm at a
ward during latter sequence might not be successful and
the control period might thus become biased. Further-
more, this design is time consuming and may not be
needed if extensive baseline assessments are done.
Moreover, because of the long wash-out period needed,
uncontrolled and unknown changes in factors associated
with the risk of ADEs may have occurred.
The participation of three different types of hospitals,
an university teaching hospital, a large teaching hospital
and a community hospital, strenghtens the general
applicability and effectiveness of ward-based pharmacy
to various clinical settings.
This study also has its limitations. First, data collec-
tion for ADEs using the trigger tool method for surgical
patients is retrospective. Information bias can play a
role in the detection of preventable ADEs. Therefore,
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detection method, it may well underestimate the num-
ber of preventable ADEs. Secondly, to perform a cost-
effectiveness analysis from a societal perspective, patients
need to complete questionnaires to include data on health
status and out-of-hospital use of resources. Without the
need of an informed consent procedure as is the case in
this study, the level of patient participation becomes less
predictable. Finally, the ward-based pharmacy intervention
has been standardized for the study, but work floor imple-
mentation may differ somewhat between different clinical
pharmacy teams. Besides, the work of the clinical phar-
macy team is partly performed by pharmacy technicians.
Nevertheless, in many - certainly European - countries
this may be easier to implement.
Although two studies have shown that decentralized
clinical pharmacy care in the ward can reduce preventa-
ble adverse drug events [16,17], this study will provide
new information to measure cost-effectiveness of clinical
pharmacy care as well as a standardized strategy to inter-
vene by a clinical pharmacy team. Searching for ways to
improve patient safety in general and medication safety
in particular remains focus of attention worldwide.
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